Co-Diagnostics

Co-Diagnostics Operating Expenses

The Total Operating Expenses of Co-Diagnostics (CODX) as of Nov 20, 2026 is 28.20 M USD. In the previous year, Total Operating Expenses was 37.14 M USD — a change of -24.08% (lower).

Operating Expenses

28.20 MUSD

YoY

-24.08%

Last updated:

Total Operating Expenses of Co-Diagnostics is 2025 28.20 M USD. Total Operating Expenses of Co-Diagnostics was 2024 37.14 M USD. It decreases by -24.08% lower compared to the previous year.

The Co-Diagnostics Operating Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Expenses
Date
Operating Expenses
Jan 1, 2018
4.93 M USD
Jan 1, 2019
4.87 M USD
Jan 1, 2020
11.46 M USD
Jan 1, 2021
26.51 M USD
Jan 1, 2022
31.70 M USD
Jan 1, 2023
37.24 M USD
Jan 1, 2024
37.14 M USD
Jan 1, 2025
28.20 M USD
The Co-Diagnostics Operating Expenses history
YEAROperating ExpensesYoY
28.20 MUSD-24.08%
37.14 MUSD-0.28%
37.24 MUSD+17.48%
31.70 MUSD+19.57%
26.51 MUSD+131.27%
11.46 MUSD+135.46%
4.87 MUSD-1.28%
4.93 MUSD+20.32%
4.10 MUSD+168.19%
1.53 MUSD-7.58%
1.65 MUSD+108.25%
794,125.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Co-Diagnostics Stock analysis

What does Co-Diagnostics do? Co-Diagnostics, Inc. develops and sells diagnostic tests using proprietary reagents and a test design system for diseases and pathogens including tuberculosis, drug-resistant tuberculosis, hepatitis B and C, malaria, dengue, HIV, and Zika virus. The company also markets self-contained lab systems (MDx devices) from other manufacturers. Its products are sold to laboratories and healthcare providers for molecular testing of organisms and genetic diseases, automating complex procedures in test development and administration. The firm generates revenue through the sale of diagnostic reagents, validated tests, and MDx devices. The company's diagnostic technology focuses on nucleic acid detection and analysis, enabling molecular testing for various pathogens and genetic conditions. Its proprietary system allows for the design and validation of tests in-house, which are then marketed to healthcare institutions. Revenue streams include reagent sales, test kits, and equipment from partner manufacturers. Co-Diagnostics, Inc. targets laboratories and healthcare providers as key customers for its diagnostic solutions. The firm's products are designed to streamline molecular testing processes, reducing the complexity of traditional methods. This approach supports the company's revenue model based on direct sales of its proprietary tests and complementary equipment. Co-Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Co-Diagnostics stock

Total Operating Expenses of Co-Diagnostics is 28.20 M USD in 2025.

Total Operating Expenses of Co-Diagnostics changed from 37.14 M USD to 28.20 M USD, representing a -24.08% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Operating Expenses Co-Diagnostics since 2006 – with annual values, charts, and detailed analysis.

Operating expenses are the costs incurred in the normal course of business operations, including COGS, SG&A, R&D, and depreciation.

Total Operating Expenses's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Operating Expenses's Co-Diagnostics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Co-Diagnostics

All Key Metrics — Co-Diagnostics